Bishop named 2019 fellow of the American Association for the Advancement of Science – Iowa Now

University of Iowa professor Gail Bishop has been named a fellow of the American Association for the Advancement of Science (AAAS), the worlds largest general-scientific society and publisher of the journal Science. Election as an AAAS Fellow is an honor bestowed upon AAAS members bytheirpeers.

As part of the Biological Sciences Section, Bishop,a professor of microbiology and immunology at the UI Roy J. and Lucille A. Carver College of Medicine, was selected for her distinguished contributions to the field of immunology, particularly for insights into regulation of T and B lymphocyteactivation.

This year, 443 members were awarded this honor by the AAAS because of their scientifically or socially distinguished efforts to advance science or itsapplications.

I am very honored by this recognition from my scientific colleagues,says Bishop, who also is associate director for basic science research at Holden Comprehensive Cancer Center at the UI, and a professor of internalmedicine.

Bishop joined the UI in 1989. Her research focuses on the molecular mechanisms that regulate the function of blood cells known as lymphocytes in normal immunity, inflammatory disease, and cancer. In particular, Bishop and her team are investigating lymphocyte signaling and interactions between innate and adaptive immune receptors. Her work has implications for treating B-cell cancers, including multiple myeloma, and developing cancervaccines.

She received a doctoral degree in cellular and molecular biology from the University of Michigan in 1983 and performed postdoctoral research at the University of North Carolina, Chapel Hill, focusing on understanding the molecular mechanisms of B lymphocyte activation and interactions between B cells and Tcells.

Bishop has served in many roles during her 30-year UI career. She was appointed as endowed College of Medicine Distinguished Professor of Microbiology in 2001 and Holden Chair of Cancer Biology in 2004; from 1998 to 2013, she directed the Immunology Graduate Program; and in 2004, she was appointed associate director for basic science research of Holden Comprehensive CancerCenter.

This is such a well-deserved honor for Dr. Bishop, who exemplifies the values that we believe make the University of Iowa great, says Brooks Jackson, UI vice president for medical affairs and the Tyrone D. Artz Dean of the UI Carver College of Medicine. As her election to the AAAS demonstrates, she is an established leader in her field of immunology, and she has coupled that scientific success with a deep commitment to training and mentoring the next generation of scientists. Her leadership within our research community has helped to shape an environment where collaboration and collegiality are valued andfostered.

Bishop also is the recipient of many awards and honors for service to the field of immunology. She served as both a section editor of The Journal of Immunology, and is on the current editorial board of the Journal of Leukocyte Biology. She has served as a grant reviewer for the National Science Foundation, the American Heart Association, and the National Institutes of Health, serving as chair of the NIH Tumors, Tolerance and Transplantation studysection.

In 2003, she received the UI Graduate Mentoring Award, and in 2009 was awarded the Iowa Technology Associations Woman of Innovation award for academic research innovation and leadership. Bishop served as president of the American Association of Immunologists in 201213, and is the director of the UI Center for Immunology and Immune-Based Diseases. She was elected as a Distinguished Fellow of the American Association of Immunologists in2019.

This years AAAS Fellows will be formally announced in the AAAS News and Notes section of the journal Science on Nov.29.

Here is the original post:
Bishop named 2019 fellow of the American Association for the Advancement of Science - Iowa Now

Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits C | BLCTT – Dove Medical Press

Manizheh Narimani,1 Mohammadreza Sharifi,2 Ali Jalili1

1Cancer and Immunology Research Center, Institute of Research for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran; 2Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence: Ali JaliliCancer and Immunology Research Center, Institute of Research for Health Development, Kurdistan University of Medical Sciences, Sanandaj, IranTel +98-9183771862Email Ali130@gmail.com

Introduction: Human Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) which encodes survivin exhibits multiple biological activities, such as cell proliferation and apoptosis. Survivin is overexpressed in numerous malignant diseases including acute myeloid leukemia (AML). Recent studies have shown that the CRISPR/Cas9 nuclease-mediated gene-editing systems are suitable approachsfor editing or knocking out various genes including oncogenes.Methods and materials: We used CRISPR-Cas9 to knockout the BIRC5 in the human leukemic cell line, HL60, and KG1, and these cell lines were transfected with either the Cas9- and three sgRNAs expressing plasmids or negative control (scramble) using Lipofectamine 3000. The efficacy of the transfection was determined by quantitative reverse transcription-polymerase chain (RT-qPCR) and surveyor mutation assays. Cell proliferation and apoptosis were measured by MTT assay and flow cytometry, respectively.Results: We have successfully knocked out the BIRC5 gene in these leukemic cells and observed that the BIRC5-knocked out cells by CRISPR/Cas9 showed a significant decrease (30 folds) of survivin at mRNA levels. Moreover, cell death and apoptosis were significantly induced in BIRC5-CRISPR/Cas9-transfected cells compared to the scramble vector.Conclusion: We demonstrated for the first time that targeting BIRC5 by CRISPR/Cas9 technology is a suitable approach for the induction of apoptosis in leukemic cells. However, further studies targeting this gene in primary leukemic cells are required.

Keywords: BIRC5, survivin, CRISPR/Cas9 nuclease, AML, KG1 cells, HL60 cell

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See more here:
Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits C | BLCTT - Dove Medical Press

Medical student and alumni discover zebrafish are resistent to eye infection – The South End

A Wayne State University School of Medicine student and two recent graduates working on a collaborative project in the laboratories of Associate Professors of Ophthalmology, Visual and Anatomical Sciences Ashok Kumar, Ph.D., and Ryan Thummel, Ph.D., have discovered that zebrafish dont contract endophthalmitis.

The eye infection can cause blindness within hours if not diagnosed and treated quickly.

Matthew Rolain, Frank Mei, M.D. 19 and Xiao Yi Zhou, M.D. 17, contributed to the study, Zebrafish are Resistant to Staphylococcus aureus Endophthalmitis, published in Pathogens, a peer-reviewed journal in the field of microbiology and immunology.

The study showed that while humans require only 10 to 100 bugs to cause endophthalmitis, and mice require 5,000 before infection, in the freshwater fish even 250,000 bacteria wont cause the eye infection. The finding indicates that zebrafish eyes are incredibly resistant to such eye infections and possess strong host defense mechanisms.

Dr. Thummel and others in the field have shown that humans and fish share similarities in eye structure and immune responses. Studying why fish, but not human eyes, are resistant, may help identify protective pathways and molecules that could be translated to humans.

Traditionally, we have used a mouse model to study the pathobiology of these infections. In recent years, zebrafish have emerged as an important model organism in biomedical research, providing insight into the pathogenic mechanisms of infectious diseases. We sought to determine their susceptibility with the ocular bacterial infection, Dr. Kumar said. I contacted my colleague Dr. Thummel and discussed the idea, and the project took off with participation of three medical students who completed the task collectively.

Dr. Kumars laboratory focuses on understanding the pathobiology of ocular infections, especially those affecting the retina, such as endophthalmitis. The infection most often occurs due to surgical complications or eye trauma.

Apart from conducting research, I truly enjoyed mentoring these medical students, Dr. Kumar said. I hope they continue develop scientific acumen as they transition to their respective residency programs.

Matthew Rolain will graduate from the School of Medicine in 2020.

Working with Dr. Kumar and Dr. Thummel was an awesome experience, he said. They gave me great guidance and were always very supportive, regardless of the outcome of our experiments. It was nice being able to learn about the research process while working on such an interesting and potentially impactful project. Hopefully the scientific community will be able to build on our results to better help future patients.

Dr. Mei is now a resident in his transitional year in Chicago before starting a two-year Ophthalmology program at the University of Texas Southwestern Medical School in Dallas.

Individually, Drs. Kumar and Thummel were well respected in their separate expertise. However, the unification of their talents into a singular project created a collaborative environment where the strengths of both labs meshed, launching and dramatically expeditingthis project to completionin a very short timeframe. Bridging the gap between Scott Hall and the KresgeEye Institute, Drs. Kumar and Thummel created a warm atmosphere to foster my growth as a researcher. This experience was invaluableand an encouragement for me to seek further collaborations in my career in academic ophthalmology, Dr. Mei said.Lastly,I would like to thank the Medical Summer Research Project through Wayne State and the Kresge Summer Internship for supporting me through this project.

Their colleague, Dr. Zhou is a resident in her transitional year at NorthShore University Health System in Illinois. She completed a one-year fellowship at Bascom Palmer Eye Institute in Miami after graduation.

Moving forward, they plan to test zebrafish susceptibility to other bacterial and fungal pathogens.

The work was supported by grants from the National Institutes of Health (R01EY027381 and R01EY026964 to Dr. Kumar, and R01EY026551 to Dr. Thummel. Histology and imaging core resources were supported by a vision core grant (P30EY04068) and an unrestricted grant from Research to Prevent Blindness to the Department of Ophthalmology, Visual and Anatomical Sciences.

See more here:
Medical student and alumni discover zebrafish are resistent to eye infection - The South End

Immunity — master regulator of liver metabolism identified during infection – Science Codex

Surprisingly, the antiviral cytokine type I interferon (IFN-I) was found to be a master regulator of metabolic pathways in liver cells. The researchers focused on the urea cycle, a central metabolic node, and found that it is disrupted by IFN-I during viral infection. This led to altered serum metabolite concentrations which regulated antiviral immunity and reduced liver pathology.

The liver is a crucial organ for systemic metabolism in our body. Apart from the turnover of biomolecules and drug metabolism, the liver's main function is the removal of toxic substances from the organism. Hepatocytes, or liver cells, are the most abundant cell type and functional unit of the liver. They are metabolic powerhouses in the healthy organism, but they also serve as important immune signaling platforms during infections. As such, they have the potential to react to a range of cytokines - small molecules that are essential for the coordination of immune responses.

Previous studies in the field of immunology and metabolism, or immunometabolism, unveiled groundbreaking mechanisms about how cells of the immune system need to adjust their metabolism to perform their functions to fight pathogens and cancer. Building on this, Andreas Bergthaler and his group at CeMM aimed to study the immunometabolic changes that occur in the whole organism during infection. They particularly focused on the liver due to its important role in controlling systemic metabolism.

To dissect the involved complex processes, the authors took advantage of the benchmark model of chronic infection, the lymphocytic choriomeningitis virus (LCMV). Research with LCMV had already led to fundamental insights into immunology over the past 80 years, and notably contributed to three Nobel Prizes. Among them is the 2018 Nobel Prize in Physiology or Medicine, which was awarded to James Allison and Tasuku Honjo for their discoveries relating to the revolutionary new cancer immunotherapies which exploit the body's own immune killer cells, or CD8 T cells.

The present study by Alexander Lercher, Anannya Bhattacharya et al. is the result of cross-disciplinary collaborations with researchers from the Medical University of Vienna and the University of Veterinary Medicine in Vienna (Austria), as well as from the Hannover Medical School (Germany), the Cantonal Hospital St. Gallen (Switzerland) and the company Bio-Cancer Treatment International Ltd (China). The study was designed as an integrative unbiased approach to investigate the molecular changes in the liver during chronic infection. Next to expected inflammatory changes, the authors identified intriguing changes in hepatocyte metabolism. Many central metabolic pathways, among them the urea cycle, were found to be repressed upon infection. The urea cycle is essential to remove toxic ammonia from the body to prevent brain damage. Surprisingly, the researchers identified the antiviral cytokine signaling pathway of type I interferons (IFN-I) as a regulator of the urea cycle. This resulted in altered blood concentrations of the amino acids arginine and ornithine. "A key experiment for us was that when we removed the receptor for IFN-I on the surface of hepatocytes, we didn't see these metabolic changes anymore", says Alexander Lercher, first author of the study and PhD student in the laboratory of CeMM Principal Investigator Andreas Bergthaler. The systemic changes of arginine and ornithine were found to inhibit antiviral CD8 T cell responses and to reduce liver damage.

One of the most important revelations of this study was the identification of IFN-I signaling as a master regulator for the repression of metabolic processes in hepatocytes upon infection. "We were really surprised that an antiviral molecule affects such vital biological processes as the urea cycle during infection", says Michael Trauner, co-author of the study and head of the Department of Gastroenterology and Hepatology at the Medical University of Vienna. Together, these findings shed new light on how the body's immune system evolved to regulate liver metabolism that modulate CD8 T cell responses and reduce collateral tissue damage during infection. Andreas Bergthaler: "We regard this study an important contribution to the field of systemic immunometabolism. It also highlights the central role of the liver for our immune system and how organs of the body communicate through metabolites." In the future, such findings may be exploited to therapeutically intervene with the regulation of metabolic processes to modulate CD8 T cell responses in diverse diseases such as infection, cancer and autoimmunity.

Excerpt from:
Immunity -- master regulator of liver metabolism identified during infection - Science Codex

Expert available to discuss Lassa virus and antibody therapies against the virus – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise Structural immunologist Dr. Erica Ollmann Saphire is available to discuss Lassa virus and current efforts to develop much-needed antibody therapies to treat often lethal Lassa infections.

A Dutch doctor, who was evacuated from Sierra Leone after contracting Lassa fever, died on November 23, while being treated at Leiden University Medical Center. A second Dutch doctor and a Sierra Leonean anesthetist have also been infected. Other Dutch and British medical personnel have been evacuated.

Lassa typically causes flu-like symptoms but can be deadly in about a quarter of infected people. There is no vaccine.

Earlier this year, Dr. Ollmann Saphire and her team identified the molecular properties shared by antibodies that are particularly efficient at inactivating Lassa virus. The beauty of structural biology is that it gives you the ability to directly see how these therapies work, says Dr. Ollmann Saphire. These high-resolution images become blueprints to engineer potent antibody therapeutics or a vaccine that elicits the desired immune response.

Bio:

Erica Ollmann Saphire, Ph.D. is a Professor of the La Jolla Institute for Immunology. Her research explains, at the molecular level, how and why viruses like Ebola and Lassa are pathogenic and provides the roadmap for medical defense. Her team has solved the structures of the Ebola, Sudan, Marburg, Bundibugyo and Lassa virus glycoproteins, explained how they remodel these structures as they drive themselves into cells, how their proteins suppress immune function and where human antibodies can defeat these viruses.

Dr. Ollmann Saphire also directs the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), which unites 43 academic, industrial and government labs across five continents. The consortiums goal is to understand which antibodies are most effective in patients and to streamline the research pipeline to provide antibody therapeutics against Ebola, Marburg, Lassa and other viruses.

Dr. Ollmann Saphire is available via email, phone and Skype.

Watch Dr. Ollmann Saphire discuss Ebola in the Democratic Republic of Congo.

Excerpt from:
Expert available to discuss Lassa virus and antibody therapies against the virus - Newswise

New way to thwart HIV infection at early stages – News-Medical.net

1.7 million. That's how many people are infected with the human immunodeficiency virus (HIV) each year worldwide. 1.7 million people who are condemned to lifelong antiretroviral therapy (ART) or risk developing fatal AIDS . Out of the 37.9 million people living with HIV (PLWH), 22.3 million have access to ART, allowing them to have an almost normal lifespan. Unfortunately, however, the medications only go so far: they don't reach the cells where the virus lies dormant for years. Moreover, potential long-term adverse effects of these medications remain unknown.

Still, HIV research has been making steady strides to help the large number of PLWH. HIV laboratories around the globe are trying to unlock the "secrets" of the virus and find its weak spots in order to prevent or cure the infection. At the Montreal Clinical Research Institute (IRCM), scientists ric A. Cohen and Tram NQ Pham have recently identified a way to thwart HIV infection at its very early stages. Their discovery is the subject of an article in the scientific journal Cell Reports.

Contrary to popular belief, HIV is not so easily transmitted. We are studying the window of vulnerability of the virus, meaning the moments in the infection process when it could be weakened or attacked. We focused on the very early stages following viral invasion.

ric Cohen, director of the Human Retrovirology Research Unit at the IRCM and a virology professor in the Department of Microbiology, Infectious Diseases and Immunology at Universit de Montral

Once transmitted, HIV does not immediately spread through the body. It initially has to multiply locally, mainly in the genital tissues. It is only after this initial, local expansion that the virus spreads. This localized expansion offers a very brief window of vulnerability before the virus efficiently establishes a systemic infection.

The immune response is like an armed struggle: an enemy infiltrates and the body defends itself. Viruses are the intruders, and white blood cells are soldiers trying to hold down the fort. The white blood cells are equipped with their own "infantry units": lymphocytes, phagocytes, granulocytes and others. The phagocyte group has an even more specialized unit known as 'plasmacytoid dendritic cells' (PDCs). These small, round-shaped cells patrol the body, specializing in both pathogen detection and antiviral response orchestration. In other words, they are the whistleblowers, the ones through which the entire defence process is set into motion. When they detect a threat, they change shape and develop protuberances called dendrites. "Most importantly, they start producing large amounts of interferon, a protein that triggers a state of infection resistance in other cells," Cohen explained.

As its name implies, HIV preferentially targets the immune system: it attacks and weakens the body's own defences, and the infected person becomes susceptible to the slightest infection. As soon as it arrives, HIV gets PDCs out of the way and prevents them from sounding the alarm. "The virus doesn't seem to kill them directly, but it makes them disappear in a way that is still not understood," said Pham, the senior research associate in the Human Retrovirology Research Unit. "The loss of PDCs from both the infection site and throughout the body helps establish the infection."

"Given what HIV does to PDCs, we wondered what would happen if we boosted PDC levels and their function both prior to and during infection," said Cohen. To test this, the scientists used a special protein known as Flt3 receptor ligand to stimulate the production of PDCs from the bone marrow of humanized mice. These rodents are engineered to have a human immune system in place of the mouse's own machinery. Consequently, in an infected humanized mouse, HIV behaves as it otherwise would in a human host.

Administration of this special protein maintained high levels of PDCs in these mice and produced some striking results: 1) the initial number of infected mice was reduced; 2) the time it took for the virus to be detectable in the blood was lengthened; and 3) the amount of virus in the blood, also known as viremia, was significantly reduced. "We observed up to a 100-fold decrease in viremia," Pham noted. "In other words, the initial infection is suppressed by maintaining a high level of PDCs."

This seminal work also showed that the injection of the Flt3 receptor ligand not only increased PDC abundance, but also boosted their ability to detect the virus and produce interferon following its detection.

Of course, HIV infection normally goes unnoticed and by the time the viremia is detectable, it is a little too late. In this context, the discovery by Cohen and Pham is highly important in terms of prevention and a potential cure. "These new findings will be crucial in the design of an HIV vaccine, which is basically aimed at teaching the immune system to defend itself by introducing it to a weakened form of the virus," said Cohen. "We can now focus on PDCs in order to control the seeding and expansion of the virus at the early stage of infection."

More here:
New way to thwart HIV infection at early stages - News-Medical.net

Gossamer Bio Announces Participation in Upcoming Investor Conferences – Yahoo Finance

SAN DIEGO--(BUSINESS WIRE)--

Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that members of the management team will participate in the following investor conferences:

A live webcast of the presentations will be available on the Events and Presentations page in the Investors section of the companys website at https://ir.gossamerbio.com. A replay of the webcast will be archived on the companys website for 90 days following the presentation.

About Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005147/en/

See the original post here:
Gossamer Bio Announces Participation in Upcoming Investor Conferences - Yahoo Finance

First-Ever Measurement of a Blue Whale’s Heartbeat Reveals Surprising Extremes – ScienceAlert

WASHINGTON (Reuters) - Using a bright orange electrocardiogram machine attached with suction cups to the body of a blue whale, scientists for the first time have measured the heart rate of the world's largest creature and came away with insight about the renowned behemoth's physiology.

The blue whale, which can reach up to 100 feet (30 meters) long and weigh 200 tons, lowers its heart rate to as little as two beats per minute as it lunges under the ocean surface for food, researchers said on Monday.

The maximum heart rate they recorded was 37 beats per minute after the air-breathing marine mammal returned to the surface from a foraging dive.

"The blue whale is the largest animal of all-time and has long fascinated biologists," said Stanford University marine biologist Jeremy Goldbogen, who led the study published in the journal Proceedings of the National Academy of Sciences.

"In particular, new measures of vital rates and physiological rates help us understand how animals work at the upper extreme of body mass," Goldbogen added. "What is life like and what is the pace of life at such a large scale?"

Generally speaking, the larger the animal, the lower the heart rate, minimizing the amount of work the heart does while distributing blood around the body.

The normal human resting heart rate ranges from about 60 to 100 beats per minute and tops out at about 200 during athletic exertion. The smallest mammals, shrews, have heart rates upwards of a thousand beats per minute.

The researchers created a tag device, encased in an orange plastic shell, that contained an electrocardiogram machine to monitor a whale's heart rhythm swimming in the open ocean. The device had four suction cups to enable them to attach it to the whale non-invasively.

The researchers obtained nine hours of data from an adult male whale about 72 feet (22 meters) long encountered in Monterey Bay off California's coast.

"First we have to find a blue whale, which can be very difficult because these animals range across vast swaths of the open ocean. By combining many years of field experience and some luck, we position a small, rigid-hulled, inflatable boat on the whale's left side," Goldbogen said.

"We then have to deploy the tag using a six-meter (20-foot) long carbon-fiber pole. As the whale surfaces to breathe, we tag the whale in a location that we think is closest to the heart: just behind the whale's left flipper," Goldbogen added.

Baleen whales such as blue whales, despite their immense size, feed on tiny prey. As filter-feeders, they take huge amounts of water into their mouths and strain out prey including shrimp-like krill and other zooplankton using baleen plates made of keratin, the same material found in fingernails.

During feeding dives, the whale exhibited extremely low heart rates, typically of four to eight beats per minute and as low as two. After surfacing to breathe following foraging dives, the whale had heart rates of 25 to 37 beats per minute.

(Reporting by Will Dunham; Editing by Sandra Maler)

Reuters

View post:
First-Ever Measurement of a Blue Whale's Heartbeat Reveals Surprising Extremes - ScienceAlert

New Dean of Science at University of Waikato – Scoop.co.nz

Wednesday, 27 November 2019, 9:43 amPress Release: University of Waikato

27 November 2019

Leading Plant PhysiologistProfessor Margaret Barbour welcomed as Dean of Science atUniversity of Waikato

Professor Margaret Barbour commencedher position as Dean of Science at the University of Waikatoon 18 November. She was previously Professor of PlantPhysiology in the School of Life and Environmental Sciencesat the University of Sydney.

Vice-Chancellor, ProfessorNeil Quigley says, We are delighted to welcome ProfessorBarbour back to the University of Waikato where she startedher tertiary education. Professor Barbour is a leadingexpert in her scientific field, and will be an asset inleading the School of Science into the future.

Experimental plant physiology is the focus of ProfessorBarbours research, and she is an internationallyrecognised expert in stable isotope effects duringphotosynthesis, respiration and transpiration of higherplants. She pioneered novel stable isotope techniques tomeasure isofluxes between plants and the atmosphere, as wellas developing an underlying theory to explain variation.

These techniques and theory have allowed newunderstanding of plant regulation of carbon and waterdynamics, with applications in crop production, plantecological physiology and paleoclimatic reconstruction fromtree rings.

Professor Barbour completed her Bachelor andMaster of Science from the University of Waikato, beforeheading overseas to complete her PhD in plant physiologyfrom the Australian National University (ANU).

Followingher PhD, Professor Barbour spent time at Landcare Researchin New Zealand, before moving back over the Tasman to takeup an Australian Research Council Fellowship at theUniversity of Sydney, and then more recently as AssociateDean of Research for the Faculty of Science.

I amdelighted to be back in my personal heartland, and excitedto contribute to the future of the University of Waikato,says Professor Barbour.

In this age of publicquestioning of scientific evidence, it is important that wescientists find new ways to connect our understanding withthat from other disciplines, with policy makers, and withthe public. I look forward to helping build theseconnections.

ENDS

Scoop Media

Scoop Citizen Membership ScoopPro for Organisations

View post:
New Dean of Science at University of Waikato - Scoop.co.nz

Illuminating the Nobels | UDaily – UDaily

From the cells in our bodies and the cell phones in our pockets, to the structure of the entire universe, the research honored by this years Nobel Prizes covers a lot of ground.

But, as is always the case at the University of Delawares annual Nobel Symposium, faculty members were able to use their own expertise to share insights into the prize-winning work with an audience of UD and community members.

As a bonus, the audience at this years event also learned about two scandals involving the prize for literature.

The symposium on Tuesday, Nov. 19, hosted by the College of Arts and Sciences in Harker Lab, featured seven short talks about this years laureates and their work, as well as a special tribute to novelist Toni Morrison, who won the Nobel Prize in Literature in 1993 and died in August.

The following are the prizes highlighted at the symposium.

Physiology or Medicine

Just as a candle needs oxygen to burn cleanly, cells need oxygen, to convert food into energy, Ramona Neunuebel, assistant professor of biological sciences, said at the symposium. But too much oxygen is deadly, and too little is deadly.

Neunuebel explained the Nobel Prize in Physiology or Medicine, which was awarded to William G. Kaelin Jr., Sir Peter J. Ratcliffe and Gregg L. Semenza for discovering how cells are able to sense and then adjust their oxygen levels. Oxygen levels can vary, depending on elevation or injury, for example, and scientists have long been puzzled by how cells are able to adapt.

The three laureates put the puzzle together by looking at different aspects of the molecular process that regulates the activity of genes. Together, they found the pathway, Neunuebel said.

She noted that, based on these discoveries, drugs are being developed to target anemia, kidney disease, cancer and other serious conditions.

Economics

Jim Berry, associate professor of economics, began his talk by pointing out that, despite billions of dollars spent each year on aid to developing countries, the question, Does this aid actually work? has been complex and difficult to answer.

But, he said, thanks to the work by this years winners of the Nobel Prize in economic sciences, a much more reliable, experimental approach has been developed. The laureates Abhijit Banerjee, Esther Duflo and Michael Kremer are all relatively young, and Duflo is only the second woman to win the economics prize, Berry said.

Their approach, which Berry termed, Start small, then go big, breaks down the factors involved in each aspect of aid. In seeking to improve education, for example, a researcher might start with the question of whether providing more textbooks to an impoverished school would make a difference in the students achievements and then randomly assign schools in the area being studied to receive or not receive more books.

(The answer? Using teaching methods that are responsive to students needs, not the quantity of textbooks, is what makes a real difference.)

This is an approach thats similar to a medical trial, Berry said. By doing more and larger randomized experiments of this type, researchers can much more accurately identify strategies that are effective, and donors can then target aid to those initiatives.

The research conducted by this years laureates has considerably improved our ability to fight global poverty, the Nobel Prize organization said in announcing the award.

Physics

Sarah Dodson-Robinson, associate professor of physics and astronomy, discussed this years Nobel Prize in Physics, awarded to three scientists, one whose work led to a new understanding of the universes history and two who discovered the first exoplanet orbiting a solar-type star.

This is all about looking for other worlds and understanding the universe, Dodson-Robinson told the audience.

James Peebles won his share of the prize for 50 years of work that is now the basis for our understanding of the universe, the Nobel organization said. His work moved cosmology [the study of the origin of the universe] from pencil and paper to science, Dodson-Robinson said.

The other recipients, Michel Mayor and Didier Queloz, made the first discovery of an exoplanet, a planet outside our Solar System, that is orbiting a solar-type star. They made the discovery in 1995, and since then, Dodson-Robinson said, Weve gone from one planet to thousands. Its been a real revolution in astronomy.

Peace

When Ethiopian Prime Minister Abiy Ahmed Ali was awarded the 2019 Nobel Peace Prize, the announcement also specifically recognized all the stakeholders working for peace and reconciliation in Ethiopia and in the East and Northeast African regions.

At UDs Nobel Symposium, Wunyabari Maloba, professor and department chair of Africana studies and professor of history, noted that the Peace Prize is intended to honor the recipient but also to encourage other leaders to undertake reforms.

Abiy took office in April 2018 and worked with Eritrean President Isaias Afwerki to resume peace talks between the two nations in their long-running border conflict. The two leaders worked out the principles of an agreement, warfare ended and the border between the two countries was reopened.

Although there have been setbacks since then, the prize should be seen as an encouragement for the reforms Abiy has implemented, Maloba said. Something to celebrate here is that half of his cabinet is composed of women, Maloba added.

The hope, he said, is that the Peace Prize will inspire other leaders to demonstrate the courage and daring to bring about peace and stability.

Chemistry

Lithium-ion batteries play a role in every part of our lives, including the battery thats in your pocket right now powering your mobile phone, said Eric Bloch, assistant professor of chemistry and biochemistry.

He explained this years Nobel Prize in Chemistry, which recognized the research conducted by John Goodenough, M. Stanley Whittingham and Akira Yoshino. The three worked separately on different aspects of building a better battery, with the result being the lightweight, rechargeable and powerful lithium-ion battery thats now used in phones, laptops and electric vehicles.

Calling the recognition overdue, Bloch said the battery will continue to play a key role in the future, especially as a means to store energy generated by wind and solar power.

If were going to transition away from fossil fuel lithium-ion batteries are how were going to do it, Bloch said. And we have these three [laureates] to thank.

Literature (2018 and 2019)

No prize was awarded last year in the literature category, after a sexual assault and financial scandal disrupted the Swedish Academys awards committee. The organization regrouped after several resignations and this year awarded two prizes.

Viet Dinh, assistant professor of English, discussed both writers who were honored Olga Tokarczuk, a Polish author who won the delayed 2018 prize, and Peter Handke of Austria, who was awarded the 2019 Nobel. The two authors, Dinh said, provide interesting counterpoints to each other, with different styles and bodies of work.

Not all of Tokarczuks books have been translated into English, and Dinh focused on those that have. He described her 2007 work, Flights, as a fascinating book composed of 116 vignettes. The extremely short stories, he said, mix fiction and fact, jump forward and back in time and can each stand alone, but together they form a constellation of themes focused on the concept of travel.

Dinh also spoke about Tokarczuks Drive Your Plow Over the Bones of the Dead, which he said has a narrower focus than the expansive Flights. The author takes a story that could be a classic whodunit mystery and transforms it into a kind of fable, he said.

While Tokarczuks body of work is smaller and has an outward focus, Handkes is much larger and more diverse, Dinh said. Hes written novels, essays, dramatic works and screenplays over more than 50 years, including The Goalkeepers Anxiety at the Penalty Kick, Offending the Audience and Wings of Desire.

The Nobel organization called him one of the most influential writers in Europe since World War II, but his controversial selection for this years prize has created another scandal. His 1996 book A Journey to the Rivers: Justice for Serbia, depicted Serbia as the victim of the 1990s Yugoslav conflict, and in 2006 he spoke at the funeral of Serbian nationalist leader Slobodan Milosevic, who died while on trial for war crimes.

The dilemma, Dinh said, is, How do you approach a work of art when the artist is known to hold [offensive or controversial] views? He suggested that, instead of ignoring the views or refusing to engage with the artists work, readers should consider also reading works by other writers that offer context and different points of view.

Special presentation honoring Toni Morrison

A. Timothy Spaulding, associate professor of English and of Africana studies, gave a tribute to 1993 laureate Toni Morrison, who is the only black woman to have won the Nobel Prize in Literature.

Calling her prose luminous and poetic, Spaulding said, It is impossible to read a Toni Morrison novel without deep feeling or contemplation.

He praised the vitality of Morrisons language and the way in which her work speaks so clearly and unflinchingly about the horrors of slavery and the legacy of racism. Even while writing about such topics, Spaulding said, Morrisons beautiful and eloquent use of language creates compelling contradictions and paradoxes.

Her work, he said, is intensely rooted in the black experience but also has a broad reach that speaks to all readers.

Morrison published her first novel, The Bluest Eye, in 1970, and went on to publish 10 other acclaimed works of fiction, including Sula, Song of Solomon and Beloved, which won the 1988 Pulitzer Prize.

This article includes information from the Nobel Prize organization.

Read this article:
Illuminating the Nobels | UDaily - UDaily